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ABSTRACT: Brain infections due to Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri often lead to death.
Despite diﬀerences in the preferential sites of infection in the brain, the mode of delivery of drugs is often intravenous. Here, we
discuss targeted therapeutic approach to aﬀect parasite viability without aﬀecting the host cells, with an eye to improve
formulation of drugs and/or administration of drugs against brain-eating amoebae.
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Among free-living amoebae, Acanthamoeba spp., Balamuthiamandrillaris and Naegleria fowleri are well-known to infect
the brain.1−3 The most distressing aspect is that the fatality rate
has remained more than 95%, despite our advances in
antimicrobial chemotherapy and supportive care. N. fowleri
produces an acute, fulminating primary amoebic meningoence-
phalitis (PAM) that results in death within days. N. fowleri gains
access via the nasal passage through contaminated water, travels
along the olfactory neuroepithelium, passes through the
cribriform plate to reach the brain, and leads to brain tissue
destruction.1−3 In contrast, Acanthamoeba and B. mandrillaris
produce chronic granulomatous amoebic encephalitis (GAE).
Acanthamoeba spp. and B. mandrillaris enter the host through
skin ulcerations and lower respiratory tract, spread hema-
togenously, and cross the blood-brain barrier to infect the brain.
Despite diﬀerences in the mode of infection, the mode of drug
delivery for both infections remains intravenous application of a
mixture of drugs (amphotericin B, sulfamethoxazole, trimetho-
prim, and rifampicin against Acanthamoeba spp.; ﬂucytosine,
ﬂuconazole, azithromycin, pentamidine, sulfadiazine, azithro-
mycin, and miltefosine against B. mandrillaris, and amphotericin
B, ﬂuconazole, rifampin, azithromycin, dexamethasone, and
miltefosine against PAM);4 however, the prognosis remains
poor, albeit these drugs being highly eﬀective in vitro. A
complete understanding of the preferential site of infection5
could lead to improved drug discovery/formulation and
application of drugs (e.g., intranasal versus intravenous) to
target this devastating infection. There are several challenges
associated with the intravenous application of drugs, including
the following: (i) high selectivity of the blood-brain barrier; (ii)
when given intravenously, drugs target all tissues primarily due
to systemic dissemination and diluting their eﬀects needlessly
and can aﬀect their physiology before reaching the target site in
the brain; (iii) drugs have to be given at high concentration to
achieve minimum inhibitory concentration at the target site
following intravenous injections, and/or drainage into the
blood following CSF injections; (iv) chemical composition of
drugs given intravenously must get through the brain
microvessels to target the intracerebral N. fowleri; (v) poor
pharmacodynamics and pharmacokinetics proﬁles of available
drugs; (vi) patient’s medical conditions; and (vii) patient’s
tolerance and Acanthamoeba susceptibility to amoebicidal
agents. Hence, there is a need to develop a targeted therapeutic
approach, or identify drugs that can aﬀect parasite viability
without aﬀecting the host cells. While reviewing several cases
reported between 1968 amd 2016, it is observed that the
location of lesions for GAE is most common in the frontal,
parietal, occipital, and temporal lobes, while lesions are most
frequent in the frontal lobe for PAM. This is consistent with the
fact that both Acanthamoeba and B. mandrillaris disseminate via
the hematogenous route, likely through the middle cerebral
artery, as these cortices are among the main regions for middle
cerebral artery supply, resulting in their widespread distribution.
Lesions due to N. fowleri are mostly found in the frontal lobe
due to anatomical proximity of olfactory bulb to the frontal
lobe, which is consistent with its entry via the nose. Thus,
intranasal application of drugs could prove to be an eﬀective
delivery method to overcome challenges of the current oral,
intraventricular, intrathecal, and intravenous methods that have
added complications of side eﬀects and/or diﬃculty in
achieving minimum inhibitory concentration at the site of the
infection, as well as avoiding the selective blood-brain barrier.
Advances in understanding the mechanisms of drugs
penetration of the central nervous system oﬀer unprecedented
opportunities for the development of novel therapeutics
interventions. Future research is needed to identify and/or
formulate drugs that can cross the biological barriers eﬀectively
without aﬀecting the host cell viability, and test chemo-
therapeutic approaches such as intranasal application of drugs
that can deliver drugs eﬀectively to the site of infection.
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